Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
32 /100
MEDIUM RISK
Score updated Aug 03, 2026

FTH — Sensei Biotherapeutics, Inc. Dilution Risk Tracker

Track FTH dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track FTH — Get alerts when the score changes →

As of August 03, 2026, Sensei Biotherapeutics, Inc. (FTH) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. Sensei Biotherapeutics, Inc. has 1.34M shares outstanding. Key dilution vectors include approximately 94 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for FTH.
🔔 Track FTH — Get forecast alerts →

Market Data

Market CapN/A
Shares Outstanding1.34M
FloatN/A
Cash$292.79M
Debt$567.0K
Short InterestN/A

Institutional Holdings

Institutional data not yet available.

Short Interest

Short Interest890.3K
Days to Cover3.8
% of FloatN/A
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-31
xbrl XBRL CONVERTIBLE 2021-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for FTH Shareholders

Sensei Biotherapeutics, Inc. (FTH) has a DilutionScore of 32/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of August 03, 2026.

DilutionWatch's EDGAR monitoring for FTH shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for FTH in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for FTH alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding FTH's Dilution Risk Factors

Primary Risk Drivers

The two most significant dilution risks for Sensei Biotherapeutics are Offering Ability and Cash Runway. Offering Ability scores at a moderate level, indicating the company has the capability to raise capital through equity offerings, which can lead to share dilution. Cash Runway is at zero, meaning the company has abundant cash reserves with no immediate concern, but this score is inverted — a value of zero represents the safest scenario. However, the company's ability to access capital markets remains a potential risk factor that could increase dilution pressure in the future.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low-risk factors. Float Risk at a minimal level suggests there is no immediate concern regarding large-scale selling by existing shareholders. Warrant Exposure also remains manageable, showing that the company’s outstanding warrants do not pose a significant dilution threat at present. A change in either area would be signaled by an increase in public float or the issuance of new warrants, which could occur in response to funding needs or strategic decisions.

SEC Filings to Watch

Several SEC filings are critical for monitoring FTH’s dilution risk profile. An S-3 registration statement would indicate plans to issue equity securities, potentially leading to share dilution. A 424B5 filing often signals a planned offering or issuance of securities and should be monitored closely. An 8-K Item 1.01 filing may report material events such as new equity offerings or capital restructuring, directly impacting shareholder ownership. Additionally, any 10-Q filings that show declining cash reserves could suggest increased reliance on future funding, thereby raising dilution risk.

How Dilution Happens

Dilution occurs when the company issues additional shares to raise capital. If Offering Ability is high, it means the company can easily access equity markets and may do so in response to funding needs or business expansion. When new shares are issued, the total number of outstanding shares increases, reducing each existing shareholder’s percentage ownership. Convertible Notes also contribute to dilution if they convert into common stock, further increasing share count and decreasing per-share value for current investors.

What Would Make This Worse

A significant deterioration in FTH’s risk profile would occur if Offering Ability increases while cash reserves decline, indicating a growing need for capital. If the company begins issuing convertible notes or warrants with low conversion prices, it could lead to substantial dilution. A shift from zero to a higher Cash Runway score would signal that the company is nearing financial strain and may be forced to issue more equity to sustain operations, increasing dilution risk for current shareholders.

Key Insight

Despite a high Offering Ability score, FTH's zero Cash Runway score indicates strong financial stability, but the potential for future capital raises remains a key concern.

How to Monitor FTH for Dilution Risk

What This Risk Level Means

A company with a medium dilution risk profile like Sensei Biotherapeutics (FTH) operates in a high-growth environment where capital is actively being raised, but without immediate signs of excessive dilution. As an operating company, FTH likely has ongoing research and development expenses that require funding, which often leads to equity issuance. The company's size and stage suggest it may be preparing for or executing a capital raise, but the current risk level indicates that while dilution is present, it is not yet at a critical point. This level of risk implies the company is managing its capital structure with some caution, though vigilance is still required to prevent escalation.

What Typically Happens Next

Companies in this profile often proceed through various funding mechanisms such as shelf registrations or ATM programs to secure capital. Warrant exercises and convertible note conversions are common drivers of dilution at this stage. FTH may be preparing for a larger capital raise, which could involve offering additional equity or converting debt into shares. The timing of such events is often influenced by clinical trial results, market conditions, or strategic partnerships. Monitoring these patterns helps anticipate when the company might issue new securities and how that could impact existing shareholders.

Monitoring Playbook

To track FTH effectively, use DilutionWatch to set up alerts for changes in dilution scores or key risk factors like Offering Ability, Warrant Exposure, and Convertible Note Risk. Check the company's filings weekly and monitor Shelf & ATM Monitor for any new registration announcements. When thresholds are hit—such as a score increase above 40/100 or a spike in warrant activity—immediately review SEC documents to assess the nature of upcoming offerings.

Early Warning Signals

Several indicators may signal worsening dilution risk. First, an increase in Offering Ability or Warrant Exposure scores beyond 45/100 suggests growing issuance plans. Second, the filing of a new shelf registration or ATM program is a strong early warning sign. Third, sudden changes in Convertible Note Risk—particularly if it spikes above 45/100—may indicate that convertible debt is nearing conversion, increasing dilution pressure.

What a Positive Resolution Looks Like

A positive shift in FTH's dilution risk profile would occur if the company secures a significant capital raise, thereby reducing reliance on future equity issuance. Alternatively, the expiration or retirement of warrants and convertible notes would lower exposure risks. Another resolution path includes strategic debt paydown or asset monetization that reduces the need for equity financing, ultimately lowering the overall dilution score.

Watch For

Any sudden spike in Offering Ability or Convertible Note Risk scores above 45/100, as these changes often precede new equity offerings that could significantly impact existing shareholders.

Full SEC filing analysis available with free account  →
Track FTH Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking FTH — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for FTH
FTH Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.